Multiprofile Hospital For Active Treatment Medical Complex Sveti Ivan Rilski EOOD
- Address
- Vassil Levski Bulevard 144a-A, 4003 Plovdiv, Bulgaria
Multiprofile Hospital For Active Treatment Medical Complex Sveti Ivan Rilski EOOD
Multiprofile Hospital For Active Treatment Medical Complex Sveti Ivan Rilski EOOD is a comprehensive clinical research facility specializing in cardiovascular and metabolic disease investigations. The center demonstrates particular expertise in evaluating novel therapeutic interventions for complex chronic conditions, with a strong focus on heart failure, chronic obstructive pulmonary disease (COPD), and diabetic complications.
- Heart failure research across the spectrum, including both reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF), as well as hypertrophic cardiomyopathy
- Chronic obstructive pulmonary disease (COPD) studies evaluating combination therapies and novel biologics for exacerbation prevention
- Type 2 diabetes complications, particularly diabetic retinopathy development and progression
- Cardiovascular-metabolic interface research examining cardiopulmonary outcomes
The institution conducts sophisticated Phase 2 and Phase 3 clinical trials involving advanced therapeutic agents including SGLT inhibitors, biologics, and combination inhalation therapies. Their research portfolio includes post-authorization safety studies and dose-finding investigations, demonstrating capability in both early and late-stage clinical development. The center's multidisciplinary approach enables comprehensive assessment of complex endpoints including biomarker evaluations, functional status measurements, and long-term safety monitoring in patients with chronic cardiopulmonary and metabolic conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1AstraZeneca AB1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB2trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Multiprofile Hospital For Active Treatment Medical Complex Sveti Ivan Rilski EOOD
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| ARTEMIS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial infarction. | Novo Nordisk A/S | Phase III | Not Recruiting | Aug 2024 | — |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Salbutamol | 2 | Unknown | 2024-02-12 | 2024-07-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.